Effectiveness of multicomponent treatment in patients with fibromyalgia: protocol for a systematic review and meta-analysis
MetadataShow full item record
Publication data (Editorial):
BioMed Central Ltd
Background: The purpose of this protocol is to provide a new systematic review with meta-analysis using the cur‑ rent methodology to compare the efectiveness of multicomponent treatment versus other interventions for patients with fbromyalgia. Methods: This protocol conforms to the Preferred Reporting Items for Systematic Review and Meta-Analysis Proto‑ cols (PRISMA-P) and the recommendations of the Cochrane Collaboration Handbook. An electronic search will be conducted in MEDLINE, EMBASE, Web of Science, Cochrane CENTRAL, LILACS, CINAHL, and PEDro, from inception until April 2022. There will be no language restrictions. The Cochrane Collaboration tool for assessing the risk of bias (RoB2) will be used. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) scale will be used to evaluate the strength of the evidence. The Hartung-Knapp-Sidik-Jonkman random efects or Mantel-Haen‑ szel fxed efects methods will be used, depending on the heterogeneity, to compute a pooled estimate of the mean diference (MD) or standardized mean diference (SMD) and respective 95% confdence intervals for clinical outcomes. Discussion: This systematic review will synthesize evidence on the efectiveness of multicomponent treatment in patients with fbromyalgia and could add important evidence in the treatment of FM to improve clinical practice and decision-making/actions in this feld. This new systematic review will try to show the efects of multicomponent treat‑ ment by type (endurance, resistance, stretching, or mind-body exercises [pilates or taichi]) and intensity (light, moder‑ ate, moderate-to-vigorous, vigorous) of exercise in patients with FM. The results will be disseminated by publication in a peer-reviewed journal. Ethics approval will not be needed because the data used for this systematic review will be obtained from individual trials and there will be no concerns about privacy. However, if we identify ethical issues dur‑ ing the development of the systematic review, these fndings will be reported in the discussion of the study. Systematic review registration: PROSPERO CRD42020142082.